The Vienna Biocenter (VBC) is in the third Viennese district in the Neu Marx area. The success story of VBC began in the 1980s with the establishment of the Institute for Molecular Pathology (IMP), the basic research center of Boehringer Ingelheim. Since the establishment of five university institutes that now form the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna, the VBC has continued to grow. In addition to the University of Applied Sciences FH Campus Wien, two institutes of the Austrian Academy of Sciences benefit from the site: The Institute for Molecular Biotechnology (IMBA) and the Gregor Mendel Institute for Molecular Plant Biology (GMI) are among the most prestigious research institutions in Austria. So far 40 ERC grants and 11 Wittgenstein prizes prove the international reputation of the scientists at the Vienna Biocenter (as of April 2017).
At the VBC, education and research combine with the strategies of successful companies and a dynamic start-up scene. Around 20 companies and nearly 500 employees take advantage of the potential for synergy. AFFiRiS AG, APEIRON Biologics AG, Arsanis Biosciences GmbH, Hookipa Biotech AG, and Valneva Austria (formerly Intercell) as well as several start-ups are working on new therapeutic approaches for socially relevant diseases. eBioscience (an Affymetrix company), Horizon Genomics GmbH, Lexogen GmbH, and Miti Biosystems GmbH are developing special products for the life science industry. The VBC is also home to the biocatalysis specialist Eucodis Bioscience GmbH, the medical device developer SCARLETRED Biomedicals GmbH, and the veterinary diagnostics specialist Labovet GmbH. Also on site is Biolution GmbH, a service provider for science communication and project management.